TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • May 10th, 2017 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
THIS TRANSITION AND SUCCESSION AGREEMENT (this “Agreement”) is entered into effective as of the 24th day of March, 2017, by and between Mylan Inc., a Pennsylvania corporation (the “Company”), and Daniel M. Gallagher (the “Executive”).
AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • May 16th, 2006 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and John P. O’Donnell (the “Executive”), is made as of April 3, 2006.
TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 6th, 2004 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
AGREEMENT, dated as of the 15th day of December, 2003 (this “Agreement”), by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and Stuart A. Williams (the “Executive”).
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 23rd, 2009 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT TO THE TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Inc. (the “Company”) and Rajiv Malik (the “Executive”), is made as of December 22, 2008.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 9th, 2005 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and Robert J. Coury (the “Executive”), is made as of December 2, 2004.
AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • April 27th, 2012 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT TO THE TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Inc. (the “Company”) and Harry A. Korman (the “Executive”), is made as of December 15, 2008.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 9th, 2005 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and Louis J. DeBone (the “Executive”), is made as of December 2, 2004.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • April 27th, 2012 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and Harry A. Korman (the “Executive”) is made as of April 3, 2006.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 9th, 2005 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and Stuart A. Williams (the “Executive”), is made as of December 2, 2004.
AMENDMENT NO. 3 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 23rd, 2009 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT TO THE TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Inc. (the “Company”) and Robert J. Coury (the “Executive”), is made as of December 22, 2008.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 26th, 2010 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT TO THE TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Inc. (the “Company”) and Daniel C. Rizzo, Jr. (the “Executive”), is made as of December 22, 2008.
AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 26th, 2010 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) is made as of this 15th day of October, 2009, by and between Mylan Inc., a Pennsylvania corporation (the “Company”), and Daniel C. Rizzo, Jr. (“Executive”).
AMENDMENT NO. 3 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 23rd, 2009 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT TO THE TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Inc. (the “Company”) and Edward J. Borkowski (the “Executive”), is made as of December 22, 2008.
HYCROFT MINING HOLDING CORPORATION Denver, CO 80237Transition and Succession Agreement • September 8th, 2020 • Hycroft Mining Holding Corp • Gold and silver ores • Colorado
This Transition and Succession Agreement (the “Agreement”) will confirm our mutual understanding and agreements regarding your assistance in facilitating a successful transition to a new President and Chief Executive Officer of Hycroft Mining Holding Corporation (“HYMC” and together with its consolidated subsidiary entities, the “Company”). Unless otherwise defined herein, capitalized terms shall have the meaning ascribed to them in the Employment Agreement dated as of March 15, 2019 between you and Hycroft Mining Corporation (the “Employment Agreement”), which agreement was assigned to and assumed by the Company effective as of the closing of the business combination between HYMC, Autar Gold Corporation (f/k/a MUDS Acquisition Sub, Inc.) and Hycroft Mining Corporation.
AMENDED AND RESTATED TRANSITION AND SUCCESSION AGREEMENT AGREEMENT, dated as of the [____] day of November 2001 (this "Agreement"), by and between Mylan Laboratories Inc., a Pennsylvania corporation (the "Company"), and [EXECUTIVE NAME] (the...Transition and Succession Agreement • February 1st, 2002 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
AMENDED AND RESTATED TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • May 12th, 2008 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDED AND RESTATED TRANSITION AND SUCCESSION AGREEMENT (this “Agreement”) is entered into as of this 31st day of December, 2007 (this “Agreement”), by and between Mylan Inc., a Pennsylvania corporation (the “Company”), and Heather Bresch (the “Executive”).
AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • May 16th, 2006 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”) and Robert J. Coury (the “Executive”), is made as of April 3, 2006.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • May 16th, 2006 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and (the “Executive”), is made as of March 31, 2006.
Transition and Succession Agreement Waiver LetterTransition and Succession Agreement • October 30th, 2015 • Mylan N.V. • Pharmaceutical preparations
Reference is made to your Transition and Succession Agreement with Mylan Inc., as such agreement has been and may be amended from time to time (the “T&S Agreement”). The T&S Agreement provides for the possibility of enhanced benefits or rights following a Change in Control (as such term is defined in the T&S Agreement) of Mylan N.V. (the “Company”). By executing this waiver letter, for good and valuable consideration (including your continued employment and continued participation in the incentive plans and programs of the Company and its subsidiaries), you acknowledge and agree that the Company’s proposed acquisition of Perrigo Company plc shall not constitute a Change in Control for any purpose of the T&S Agreement. All other provisions of the T&S Agreement, as modified by the foregoing, shall remain in full force and effect notwithstanding this waiver letter.
AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • February 9th, 2005 • Mylan Laboratories Inc • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 1 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) by and between Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), and John P. O’Donnell (the “Executive”), is made as of December 2, 2004.
Transition and Succession Agreement Waiver LetterTransition and Succession Agreement • March 2nd, 2015 • Mylan Inc. • Pharmaceutical preparations
Reference is made to your Transition and Succession Agreement with Mylan Inc. (the “Company”), as such agreement has been and may be amended from time to time (the “T&S Agreement”). The T&S Agreement provides for the possibility of enhanced benefits or rights following a Change in Control of the Company (as such term is defined in the T&S Agreement). By executing this waiver letter, for good and valuable consideration (including your continued employment and continued participation in the Company’s incentive plans and programs), you acknowledge and agree that the transactions consummated pursuant to the Business Transfer Agreement and Plan of Merger, dated as of July 13, 2014, by and among Abbott Laboratories, an Illinois corporation, the Company and the other parties thereto, as such agreement may be amended from time to time, shall not constitute a Change in Control for any purpose of the T&S Agreement. All other provisions of the T&S Agreement, as modified by the foregoing, shall re
RECITALSTransition and Succession Agreement • June 26th, 2001 • Mylan Laboratories Inc • Pharmaceutical preparations
HYCROFT MINING HOLDING CORPORATION Denver, CO 80237Transition and Succession Agreement • July 2nd, 2020 • Hycroft Mining Holding Corp • Gold and silver ores • Colorado
This Transition and Succession Agreement (the “Agreement”) will confirm our mutual understanding and agreements regarding your assistance in facilitating a successful transition to a new President and Chief Executive Officer of Hycroft Mining Holding Corporation (“HYMC” and together with its consolidated subsidiary entities, the “Company”). Unless otherwise defined herein, capitalized terms shall have the meaning ascribed to them in the Employment Agreement dated as of March 15, 2019 between you and Hycroft Mining Corporation (the “Employment Agreement”), which agreement was assigned to and assumed by the Company effective as of the closing of the business combination between HYMC, Autar Gold Corporation (f/k/a MUDS Acquisition Sub, Inc.) and Hycroft Mining Corporation.
AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • April 27th, 2012 • Mylan Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT NO. 2 TO TRANSITION AND SUCCESSION AGREEMENT (this “Amendment”) is made as of this 15th day of October, 2009, by and between Mylan Inc., a Pennsylvania corporation (the “Company”), and Anthony Mauro (“Executive”).
